

## WEST Search History

DATE: Monday, August 06, 2007

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L7	l6 and \$renin	3
<input type="checkbox"/>	L6	L5 and (high near5 hlb)	41
<input type="checkbox"/>	L5	L4 and (low near5 hlb)	70
<input type="checkbox"/>	L4	L3 and l2 and l1	448
<input type="checkbox"/>	L3	(hlb near3 surfactant\$).ti,ab,clm.	4873
<input type="checkbox"/>	L2	(hydrophilic or hydro-philic).ti,ab,clm.	122960
<input type="checkbox"/>	L1	(lipophilic or lipo-philic or lipidphilic or lipid-philic).ti,ab,clm.	15940

END OF SEARCH HISTORY

1. 20070123431. 29 Nov 05. 31 May 07. Polymer hydration method using microemulsions. Jones; Thomas A., et al. 507/209; 507/219 C09K8/00 20060101 E21B43/00 20060101

---

- ☐ 2. 20070082016. 17 Dec 04. 12 Apr 07. Microemulsion preconcentrate comprising a renin inhibitor. Ottinger; Isabel. 424/400; 514/616 A61K31/165 20060101 A61K9/00 20060101

---

- ☐ 3. 20060275358. 01 Jun 05. 07 Dec 06. Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10. Lin; Jing. 424/451; 424/94.1 A61K38/43 20070101 A61K9/48 20070101

---

- ☐ 4. 20060205639. 28 Feb 06. 14 Sep 06. Pro-nanodispersion for the delivery of cyclosporin. Domb; Abraham J., et al. 514/11; 977/906 A61K38/13 20060101

---

- ☐ 5. 20060035789. 10 Aug 04. 16 Feb 06. Surfactant package for well treatment and method using same. Mas; Manuel, et al. 507/261; C09K8/60 20060101 E21B43/00 20060101

---

- ☐ 6. 20060014788. 08 Sep 05. 19 Jan 06. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors. Gumkowski; Michael J., et al. 514/313; A61K31/4706 20060101

---

- ☐ 7. 20050158389. 14 Oct 04. 21 Jul 05. Dispersible concentrate lipospheres for delivery of active agents. Domb, Abraham J.. 424/489; A61K009/14.

---

- ☐ 8. 20050079185. 26 Jul 04. 14 Apr 05. Vaccine formulations. Parisot, Alexis Guy Andre, et al. 424/184.1; A61K039/00 A61K039/295.

---

- ☐ 9. 20050045849. 12 May 04. 03 Mar 05. Methods for preventing and/or extinguishing fires. Sortwell, Edwin T.. 252/8.05; A62D001/00.

---

- ☐ 10. 20040115161. 26 Sep 03. 17 Jun 04. Cosmetic emulsion preparation and agent for external use. Oyama, Keiichi, et al. 424/70.31; A61K007/075 A61K007/08.

---

- ☐ 11. 20030125211. 14 Nov 01. 03 Jul 03. Adjuvant blend for enhancing efficacy of pesticides. Woznica, Zenon J., et al. 504/363; 504/214 504/215 504/234 504/253 504/273 504/343 504/347 504/353 A01N025/04 A01N025/16 A01N047/36 A01N043/68 A01N043/48 A01N043/653 A01N035/10 A01N047/40 A01N033/18 A01N031/00.

---

- ☐ 12. 20030022944. 19 Jun 02. 30 Jan 03. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors. Gumkowski, Michael J., et al. 514/786; A61K047/00.

---

- ☐ 13. 20030005853. 30 May 02. 09 Jan 03. Fragrant ink-jet ink. Leu, Yi-Jing, et al. 106/31.02; 106/31.27 106/31.58 106/31.6 106/31.86 C09D011/00.

---

- ☐ 14. 20020061873. 15 Aug 01. 23 May 02. Spontaneously dispersible N-benzoyl staurosporine compositions. Matthews, Graham Paul, et al. 514/211.08; 514/552 A61K031/553 A61K031/23.

---

- ☐ 15. 7026290. 30 Dec 99; 11 Apr 06. Dispersible concentrate for the delivery of cyclosporin. Domb; Abraham J.. 514/11; 514/9. A61K38/13 20060101 .

---

- ☐ 16. 6962931. 19 Jun 02; 08 Nov 05. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors. Gumkowski; Michael J., et al. 514/313; 514/312 514/314 514/451 514/452 514/455.

A61K031/47 A61K031/35 A61K031/335 .

---

☐ 17. 6706098. 30 May 02; 16 Mar 04. Fragrant ink-jet ink. Leu; Yi-Jing, et al. 106/31.02; 106/31.27 106/31.58 106/31.6 106/31.86. C09D011/00 .

---

☐ 18. 6642178. 14 Nov 01; 04 Nov 03. Adjuvant blend for enhancing efficacy of pesticides. Woznica; Zenon J., et al. 504/211; 504/234 504/235 504/253 504/343 504/363 71/54 71/59 71/61. C05G003/02 C05G003/06 C05C001/00 C05C011/00 A01N025/30 .

---

☐ 19. 6191105. 27 Oct 97; 20 Feb 01. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin. Ekwuribe; Nnochiri Nkem, et al. 514/3; 424/400 424/455 514/2. A61K038/38 C07K014/62 .

---

☐ 20. 6008192. 12 Mar 98; 28 Dec 99. Hydrophilic binary systems for the administration of lipophilic compounds. Al-Razzak; Laman A., et al. 514/11; 514/885 514/975. A61K009/10 A61K009/50 A61K047/34 .

---

☐ 21. 5908697. 08 Dec 97; 01 Jun 99. Active principle carriers containing non-ionic surfactants, and uses thereof, particularly in food, cosmetics and pharmaceuticals. Roux; Didier, et al. 428/402.2; 428/402.21 428/402.22 428/402.24. A23P001/04 .

---

☐ 22. 5656289. 16 Feb 94; 12 Aug 97. Pharmaceutical formulations that have a biologically active hydrophilic phase and a chylomicra-containing hydrophobic phase. Cho; Young W., et al. 424/455; 424/450 424/451 424/456 424/463 514/2 514/21 514/3 514/866 514/937 514/938 514/941 514/943. A61K009/107 A61K009/48 A61K009/127 .

---

☐ 23. 5626655. 17 Apr 96; 06 May 97. Use of co-surfactants to adjust properties of ink-jet inks. Pawlowski; Norman E., et al. 106/31.27; 106/31.43 106/31.59 347/100. C09D011/02 .

---

☐ 24. 5444041. 20 May 92; 22 Aug 95. Convertible microemulsion formulations. Owen; Albert J., et al. 514/2; 424/193.1 424/400 424/94.3. A61K009/107 A61K038/00 A61K038/16 A61K039/00 .

---

☐ 25. 4906701. 30 Sep 88; 06 Mar 90. Inverse emulsion polymerization. Clark, Jr.; Earl. 526/207; 526/209 526/264. C08F002/32 .

---

☐ 26. 4795643. 29 Jun 87; 03 Jan 89. Medicament with a delayed release of active ingredient. Seth; Pawan. 424/456; 424/455 424/457. A61K009/64 .

---

☐ 27. 4764574. 09 Dec 86; 16 Aug 88. Inverse emulsion polymerization with sorbitan fatty acid esters and ethoxylated alcohol. Clark, Jr.; Earl. 526/207; 526/287 526/911. C08F002/32 .

---

☐ 28. 4536323. 28 Jun 83; 20 Aug 85. Non-flammable aerosol propellant microemulsion system. Stopper; Howard R.. 516/8.1; 252/70 510/406 510/417 510/424 510/506 524/903. C09K003/30 .

---

☐ 29. 4325861. 03 Apr 80; 20 Apr 82. Rapidly dissolved water-soluble polymer composition. Braun; David B., et al. 523/205; 106/174.1 524/37 524/38 524/41. C08K005/01 .

---

☐ 30. JP02000345146A. 03 Jun 99. 12 Dec 00. COMPOSITION FOR CRACKING FOAM. ISOMURA, MITSUAKI. C09K003/30; A61K007/00 .

---

☐ 31. WO009408605A1. 15 Oct 93. 28 Apr 94. THERAPEUTIC MICROEMULSIONS. CONSTANTINIDES, PANAYIOTIS PERI. A61K037/00;.

---

☐ 32. WO009302665A1. 24 Jul 92. 18 Feb 93. W/O MICROEMULSIONS. CONSTANTINIDES, PANAYIOTIS PERI. A61K009/107;.

---

☐ 33. WO009302664A1. 24 Jul 92. 18 Feb 93. W/O MICROEMULSIONS. CONSTANTINIDES, PANAYIOTIS PERI. A61K009/107;.

---

☐ 34. US20030125211A. Adjuvant blend used in spray carriers containing herbicides for controlling e.g. weeds, comprises nitrogen fertilizer, pH adjuster, modified vegetable oil, and blend of nonionic surfactants of different hydrophilic lipophilic balance. MESSERSMITH, C, et al. A01N025/04 A01N025/16 A01N025/30 A01N031/00 A01N033/18 A01N035/10 A01N043/48 A01N043/653 A01N043/68 A01N047/36 A01N047/40 C05C001/00 C05C011/00 C05G003/02 C05G003/06.

---

☐ 35. WO 9419003A. Stable, self-emulsifying microemulsions for drug delivery - contain medium chain fatty acid ester(s) of propylene glycol or a poly-ol and a low HLB surfactant, a poly-ol and a high HLB surfactant am aq. phase and a drug. CONSTANTINIDES, P P. A61K009/107 A61K037/02 A61K038/00 A61K038/22 A61K038/28.

---

☐ 36. WO 9419001A. Stable, self-emulsifying micro-emulsions for drug delivery - contain a medium chain fatty acid tri:glyceride and a low HLB surfactant, a poly:ol and a high HLB surfactant, an aq. phase and a drug. CONSTANTINIDES, P, et al. A61K009/107 A61K037/02 A61K038/00 A61K038/11 A61K038/22 A61K038/23 A61K038/28.

---

☐ 37. WO 9419000A. Stable self-emulsifying microemulsion for drug delivery - contg. oil and surfactant system contg. mixt. of high and low HLB surfactants, aq. phase and drug.. CONSTANTINIDES, P, et al. A61K009/107 A61K009/22 A61K009/66 A61K037/02 A61K037/26 A61K038/00 A61K038/11 A61K038/22 A61K038/23 A61K038/28.

---

☐ 38. WO 9408605A. Water-in-oil microemulsion as oral or topical drug delivery vehicle - used for peptide(s), insulin, calcitonin, somatostatin, growth hormone, etc, and enhances oral bio:availability. CONSTANTINIDES, P, et al. A61K009/107 A61K037/00 A61K038/00 A61K038/04 A61K038/23 A61K038/28 A61K047/14.

---

☐ 39. WO 9408603A. Water in oil microemulsion useful as oral or topical drug delivery vehicle partic. for peptide(s) - comprises lipophilic phase contg inter-esterified tri:glyceride and low HLB surfactant, high HLB surfactant, aq hydrophilic phase etc. CONSTANTINIDES, P, et al. A61K037/00 A61K037/02 A61K037/26 A61K038/00 A61K038/04 A61K038/11 A61K038/23 A61K038/28 A61K047/06.

---

☐ 40. EP 597029B. Stable water-in-oil microemulsion - with lipophilic phase of long-chain fatty acid tri:glyceride and low HLB surfactant, hydrophilic phase contg. drug and high HLB surfactant. CONSTANTINIDES, P P, et al. A61K000/00 A61K009/107 A61K009/113 A61K037/00 A61K037/02 A61K037/26 A61K037/30 A61K037/34 B01F017/00 B01F017/44 B01J013/00.

---

☐ 41. EP 597007B. Water-in-oil microemulsion reducing stomach and duodenum irritation - has lipophilic phase of medium-chain fatty acid tri:glyceride and low HLB surfactant and hydrophilic phase contg. drug and high HLB surfactant. CONSTANTINIDES, P P, et al. A61K000/00 A61K009/107 A61K009/113 A61K037/00 A61K037/02 A61K037/24 A61K037/26 A61K037/30 A61K037/34 B01F003/08.

[Generate Collection](#)[Print](#)

Term	Documents
HIGH	8290091
HIGHS	3340
HLB	25180
HLBS	319
(5 AND (HLB NEAR5 HIGH)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	41
(L5 AND (HIGH NEAR5 HLB)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	41

[Prev Page](#) [Next](#)

## Hit List

[First Hit](#)[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 20070082016 A1

L7: Entry 1 of 3

File: PGPB

Apr 12, 2007

DOCUMENT-IDENTIFIER: US 20070082016 A1

TITLE: Microemulsion preconcentrate comprising a renin inhibitor

Abstract Paragraph:

The present invention relates to pharmaceutical compositions for oral administration comprising a .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide renin inhibitors as the active ingredient. In particular, the present invention relates to galenic formulations in the form of microemulsion preconcentrates comprising the active ingredient and at least one absorption enhancing excipient which preconcentrates provide spontaneously dispersible water-in-oil microemulsions which upon further dilution in aqueous medium, e.g., gastric fluids, convert to oil-in-water microemulsions. The present invention also relates to the processes for their preparation and to their use as medicaments.

Brief Summary Text:

[0002] The .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide derivatives are a class of potent renin inhibitors which present highly specific difficulties in relation to administration generally and galenic formulation in particular, including problems of drug bioavailability and variability in inter- and intra-subject dose response thus necessitating development of a non-conventional dosage form.

Brief Summary Text:

[0004] The use of lipid-based microemulsions to enhance the bioavailability of different drugs, including peptides, has already been described, e.g., in GB 2,222,770 and International PCT Patent Application No. WO 94/08605. Thus, GB 2,222,770 discloses microemulsions and corresponding microemulsion preconcentrates for use with the highly hydrophobic cyclosporin peptides. Accordingly, a suitable preconcentrate comprises 1,2-propylene glycol as the hydrophilic component, a caprylic-capric acid triglyceride as the lipophilic component and a mixture of a polyoxyethylene glycolated hydrogenated castor oil and glycerin monooleate (ratio 11:1) as the surfactant-cosurfactant. Such formulations may then be diluted with water, to give o/w rather than w/o microemulsions. WO 94/08605 describes self-emulsifying w/o microemulsions which comprise (i) a lipophilic phase in which the oil and the low HLB surfactant are a physical mixture of medium and long chain fatty acid components; (ii) a high HLB surfactant; and (iii) an aqueous hydrophilic phase comprising a water soluble therapeutic agent.

Brief Summary Text:

[0010] In accordance with the present invention it has now been found that stable pharmaceutical compositions with .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide renin inhibitors, having particularly interesting bioavailability characteristics and reduced variability in inter- and intra-subject

bioavailability parameters, are obtainable as microemulsion preconcentrates, in particular, as w/o preconcentrates. The compositions of the present invention comprise at least one excipient that enhance the oral absorption of the active ingredient either by inhibition of efflux or by enhancing transcellular absorption, e.g., by increasing membrane fluidity, and thereby would substantially reduce the difficulties encountered previously. It has been shown that the compositions in accordance with the present invention may enable effective dosaging with concomitant enhancement as well as reduced variability of absorption/bioavailability levels for and between individual subjects. Thus, the invention may achieve effective therapy with tolerable dosage levels of such .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide derivatives, and may permit closer standardization and optimization of daily dosage requirements for each individual. Consequently, occurrence of potential undesirable side-effects may be diminished and overall cost of therapy may be reduced.

Brief Summary Text:

[0011] The .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide derivatives to which the present invention applies are any of those having renin inhibitory activity and, therefore, pharmaceutical utility, e.g., as therapeutic agents for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

Brief Summary Text:

[0012] Accordingly, the present invention provides a pharmaceutical composition comprising a 8-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide renin inhibitor as the active ingredient in an absorption enhancing carrier medium comprising:

Brief Summary Text:

(b) a high HLB surfactant; and

Brief Summary Text:

[0013] Preferably, the lipophilic component comprises a low HLB surfactant.

Brief Summary Text:

[0014] More preferably, the lipophilic component comprises a low HLB surfactant which is based on a medium or a long chain fatty acid, or a mixture of fatty acids thereof, and an oil which is a medium or a long chain fatty acid triglyceride, or a mixture of triglycerides thereof.

Brief Summary Text:

[0015] Most preferably, the lipophilic component comprises a low HLB surfactant which is based on a medium chain fatty acid, or a mixture of fatty acids thereof, and an oil which is a medium chain fatty acid triglyceride, or a mixture of triglycerides thereof.

Brief Summary Text:

[0017] Advantageously, the components of the absorption enhancing carrier medium of the present invention may all be composed of absorption enhancing excipients. However, only one absorption enhancing component may be sufficient, e.g., the high HLB surfactant.

Brief Summary Text:

[0019] Preferably, a .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide

renin inhibitor of the present invention has the formula wherein R.sub.1 is C.sub.1-4alkoxy-C.sub.1-4alkoxy or C.sub.1-4alkoxy-C.sub.1-4alkyl; R.sub.2 is C.sub.1-4alkyl or C.sub.1-4alkoxy; and R.sub.3 and R.sub.4 are independently branched C.sub.3-4alkyl; or a pharmaceutically acceptable salt thereof.

Brief Summary Text:

[0020] More preferably, the .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide renin inhibitor of the present invention is a compound of formula (I) wherein R.sub.1 is 3-methoxypropoxy; R.sub.2 is methoxy; and R.sub.3 and R.sub.4 are isopropyl; or a pharmaceutically acceptable salt thereof.

Brief Summary Text:

[0021] Most preferably, the .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide renin inhibitor of the present invention is (2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (2-carbamoyl-2-methyl-propyl)-amide hemifumarate, also known as aliskiren.

Brief Summary Text:

[0031] Suitable low HLB surfactants for use in the present invention include, but are not limited to, fatty acid mono- and diglycerides, as well as mixtures thereof, and may also comprise a small amount by weight of free fatty acid. The mono- and diglycerides may each include blends of different fatty acid mono- and diglycerides.

Brief Summary Text:

[0032] Suitable medium chain fatty acid mono- and diglycerides are formed from caprylic and capric acids. Suitable blends comprise from about 50 to 100% caprylic acid and from about 0 to about 50% capric acid mono and/or diglycerides. Suitable commercial sources of these include, but are not limited to, absorption enhancing low HLB surfactants available under the trade name CAPMUL (Karlsham Lipid Specialties, Columbus Ohio), e.g., CAPMUL MCM which comprises monoglycerides (77.4%), diglycerides (21%) and free glycerol (1.6%), with a fatty acid composition of caproic acid (3.2%), caprylic acid (66.8%), capric acid (29.6%), lauric acid (0.3%) and palmitic acid (0.1%) and CAPMUL MCM C8 which has monoglycerides (70-90%), diglycerides (10-30%) and free glycerol (2-4%), with a fatty acid composition which comprises at least 98% of caprylic acid (manufacturers data).

Brief Summary Text:

[0035] Preferably, the low HLB surfactant will have an HLB value in the range of from about 2.5 to about 6, e.g., the HLB value of CAPMUL MCM is about 5.5.

Brief Summary Text:

[0036] Suitably, the lipophilic phase comprising the oil and the low HLB surfactant together may be present from about 15 to about 80% by weight of the total composition of the present invention, preferably, from about 20 to about 70% by weight and, more preferably, from about 30% to about 60% by weight.

Brief Summary Text:

[0037] The high HLB surfactants suitable for use in the present invention include, but are not limited to, non-ionic efflux inhibiting and thereby absorption enhancing surfactants such as: [0038] (a) Polyoxyethylene fatty acid esters, e.g., polyoxyethylene stearic acid esters of the type available under the trade name MYRJ, e.g., MYRJ 52 (a polyoxyethylene 40 stearate). Other related products include polyethoxylated saturated hydroxy fatty acids which may be produced by reacting a saturated hydroxy fatty acid, e.g., C.sub.18 to C.sub.20 fatty acid, with ethylene oxide or polyethylene glycol. Suitable examples for the present invention include those known in the art and commercially available, e.g., from the BASF company under the trade mark SOLUTOL. Especially preferred is SOLUTOL HS15 which is known, e.g., from the BASF technical leaflet MEF 151E (1986), to comprise of about 70% polyethoxylated 12-hydroxystearate by weight and about 30% by weight unesterified



polyethylene glycol component; [0039] (b) Polyoxyethylene-sorbitan fatty acid esters (polysorbates), e.g., the mono- and tri-lauryl, palmityl, stearyl and oleyl esters, for instance the polyoxyethylene sorbitan monooleates available under the trade name of TWEEN, such as TWEEN 20, 21, 40, 60, 61, 65, 80, 81 and 85, of which class TWEEN 80 (polysorbat 80) is especially preferred; [0040] (c) Reaction products of a natural or hydrogenated castor oil and ethylene oxide. The natural or hydrogenated castor oil may be reacted with ethylene oxide in a molar ratio of from about 1:35 to about 1:60, with optional removal of the polyethyleneglycol component from the products. Various such surfactants are commercially available. Particularly suitable surfactants include polyethyleneglycol-hydrogenated castor oils available under the trade name CREMOPHOR, e.g., CREMOPHOR RH 40 (polyoxyl 40 hydrogenated castor oil) and CREMOPHOR EL (polyoxyl 35 castor oil); [0041] (d) Polyoxyethylene-polyoxypropylene co-polymers and block co-polymers, poloxamers, e.g., of the type known and commercially available under the trade names PLURONIC, LUTROL and MONOLAN. An especially preferred product of this class is PLURONIC F68 (poloxamer 188) from BASF, having a melting point of about 52.degree. C. and a molecular weight of about 6800 to 8975; [0042] (e) Polyoxyethylene glycol long-chain alkyl ethers, such as polyoxyethylated glycol lauryl ether; [0043] (f) Polyoxyethylene glycol long-chain alkyl esters, such as PEG-monostearate; and [0044] (g) Water soluble tocopheryl polyethylene glycol succinic acid esters (TPGS), e.g., those with a polymerization number ca 1000, e.g., VITAMIN E-TPGS, available from Eastman Fine Chemicals Kingsport, Texas, USA.

Brief Summary Text:

[0045] For use herein, the high HLB surfactant preferably has an HLB value in the range of 13 to 20.

Brief Summary Text:

[0046] The high HLB surfactant may comprise from about 5 to about 60% by weight of the total composition of the present invention, preferably, from about 10 to about 50% by weight.

Brief Summary Text:

[0047] Preferably, the blend of low and high HLB surfactants will have an HLB value in the range of from about 7 to about 15, more preferably from about 8 to about 13.

Brief Summary Text:

[0050] Preferably the relative proportions of the lipophilic component, the hydrophilic component, and the high HLB surfactant lie within the "Microemulsion" region on a standard three way plot graph. These phase diagrams may be generated in a conventional manner as described, e.g., in GB 2,222,770 and International PCT Patent Application No. WO 96/13273.

Brief Summary Text:

[0062] The microemulsion preconcentrates of the present invention, preferably, in the form of a w/o microemulsion, are formed spontaneously or substantially spontaneously when their components are brought into contact, that is without the application of substantial energy supply. For instance, in the absence of high shear energy such as imparted by homogenization and/or microfluidization or other mechanical agitation. Accordingly, the microemulsion preconcentrates may be readily prepared by the simple process of admixing appropriate quantities with gentle mixing or stirring if necessary to ensure thorough mixing. Preferably, the therapeutic agent is dissolved in the hydrophilic phase, either directly or by dilution of a stock solution thereof, and this may then be added to a pre-mixed combination of the oil and the low HLB surfactant with mixing, followed by the high HLB surfactant or vice versa. Alternatively, a drug-free microemulsion preconcentrate may be initially prepared by admixing the oil, the low HLB surfactant, the high HLB surfactant and the hydrophilic component, to which composition may then be added the therapeutic agent. Whilst higher temperatures

(40-60.degree. C.) may be needed to solubilize all components during the preparation of the microemulsion preconcentrate, the preferred systems may be formulated at room temperature.

Brief Summary Text:

[0063] As defined herein, the active ingredient or the therapeutic agent refers to any .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide derivative which exhibits renin inhibitory activity as may be determined by standard in vitro and in vivo tests known in the art, e.g., by those disclosed in U.S. Pat. No. 5,559,111. The .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide derivatives may be prepared according to literature procedures, e.g., those described in U.S. Pat. No. 5,559,111.

Brief Summary Text:

[0064] In a preferred aspect, the present invention provides pharmaceutical compositions in the form of microemulsion preconcentrates comprising at least one absorption enhancing excipient which compositions provide spontaneously dispersible w/o microemulsions which upon further dilution in aqueous medium, e.g., gastric fluids, convert to o/w microemulsions, and a .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide renin inhibitor which may be orally administered and which will retain its biological activity, thereby overcoming the disadvantages of earlier formulations in which the bioavailability of the .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide derivatives has been less than satisfactory.

Brief Summary Text:

[0068] Ultimately, the present invention provides for the use of a fatty acid triglyceride, a low HLB surfactant, a high HLB surfactant, a hydrophilic component and a therapeutic agent as hereinbefore defined in the manufacture of a medicament.

Brief Summary Text:

[0069] Thus, the present invention relates to use of pharmaceutical compositions as described herein above for the manufacture of a medicament for the treatment of conditions mediated by renin activity, preferably, hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

Brief Summary Text:

[0072] The microemulsion preconcentrates of the illustrative Examples may generally be prepared by first dissolving the appropriate amount of the therapeutic agent, e.g., aliskiren, in the hydrophilic component, e.g., PEG 300, with stirring if necessary to obtain complete dissolution. The hydrophilic phase containing the drug is then added to the appropriate amounts (by weight) of a mixture of the oil and the low HLB surfactant, to which is then added the high HLB surfactant, with gentle stirring. Alternatively, the hydrophilic phase containing the drug is added to the high HLB surfactant and following upon complete mixing, this is added to the oil plus low HLB surfactant mixture. If necessary, the drug-containing microemulsion preconcentrate is then diluted with the corresponding drug-free microemulsion to adjust the concentration of the drug.

CLAIMS:

1. A pharmaceutical composition for oral administration comprising a .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide renin inhibitor in an absorption

enhancing carrier medium comprising: (a) a lipophilic component; (b) a high HLB surfactant; and (c) a hydrophilic component; which composition upon admixing forms a stable microemulsion preconcentrate.

2. A pharmaceutical composition according to claim 1, wherein the lipophilic component comprises a low HLB surfactant.

3. A pharmaceutical composition according to claim 2, wherein the lipophilic component comprises a low HLB surfactant which is based on a medium or a long chain fatty acid, or a mixture of fatty acids thereof, and an oil which is a medium or a long chain fatty acid triglyceride, or a mixture of triglycerides thereof.

4. A pharmaceutical composition according to claim 3, wherein the lipophilic component comprises a low HLB surfactant which is based on a medium chain fatty acid, or a mixture of fatty acids thereof, and an oil which is a medium chain fatty acid triglyceride, or a mixture of triglycerides thereof.

6. A pharmaceutical composition according to claim 4, wherein the .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide renin inhibitor has the formula wherein R.sub.1 is C.sub.1-4alkoxy-C.sub.1-4alkoxy or C.sub.1-4alkoxy-C.sub.1-4alkyl; R.sub.2 is C.sub.1-4alkyl or C.sub.1-4alkoxy; and R.sub.3 and R.sub.4 are independently branched C.sub.3-4alkyl; or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition according to claim 6, wherein the .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide renin inhibitor is a compound of formula (I) wherein R.sub.1 is 3-methoxypropoxy; R.sub.2 is methoxy; and R.sub.3 and R.sub.4 are isopropyl; or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition according to claim 7, wherein the .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide renin inhibitor is (2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (2-carbamoyl-2-methyl-propyl)-amide hemifumarate.

10. A pharmaceutical composition according to claim 6, wherein the medium chain fatty acids of the lipophilic component have from 8 to 12 carbon atoms.

12. A pharmaceutical composition according to claim 6, wherein the low HLB surfactant has an HLB value ranging from about 2.5 to about 6.

13. A pharmaceutical composition according to claim 6, wherein the high HLB surfactant has an HLB value ranging from about 13 to about 20.

14. A pharmaceutical composition according to claim 13, wherein the high HLB surfactant is selected from polysorbate 80, macrogol-15 hydroxystearate, vitamin E-TPGS and polyoxyl 40 hydrogenated castor oil.

15. A pharmaceutical composition according to claim 6, wherein the hydrophilic phase comprises PEG 300.

16. A pharmaceutical composition according to claim 15, wherein the medium chain fatty acids of the lipophilic component have from 8 to 12 carbon atoms.

17. A pharmaceutical composition according to claim 16, wherein the low HLB surfactant has an HLB value ranging from about 2.5 to about 6.

18. A pharmaceutical composition according to claim 17, wherein the high HLB surfactant has an HLB value ranging from about 13 to about 20.

19. A pharmaceutical composition according to claim 18, wherein the .delta.-amino-

.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide renin inhibitor is a compound of formula (I) wherein R.sub.1 is 3-methoxypropoxy; R.sub.2 is methoxy; and R.sub.3 and R.sub.4 are isopropyl; or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition according to claim 19, wherein the high HLB surfactant is selected from polysorbate 80, macrogol-15 hydroxystearate, vitamin E-TPGS and polyoxyl 40 hydrogenated castor oil.

22. A pharmaceutical composition according to claim 19, wherein the .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide renin inhibitor is (2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (2-carbamoyl-2-methyl-propyl)-amide hemifumarate.

24. A pharmaceutical composition according to claim 23, wherein the high HLB surfactant is selected from polysorbate 80, macrogol-15 hydroxystearate, vitamin E-TPGS and polyoxyl 40 hydrogenated castor oil.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: WO 9408605 A1, EP 666752 A4, EP 666752 A1, JP 08502492 W

L7: Entry 2 of 3

File: DWPI

Apr 28, 1994

DERWENT-ACC-NO: 1994-150935

DERWENT-WEEK: 199702

COPYRIGHT 2007 DERWENT INFORMATION LTD

TITLE: Water-in-oil microemulsion as oral or topical drug delivery vehicle - used for peptide(s), insulin, calcitonin, somatostatin, growth hormone, etc, and enhances oral bio:availability

INVENTOR: CONSTANTINIDES, P; CONSTANTINIDES, P P

PRIORITY-DATA: 1992US-0962957 (October 16, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9408605 A1	April 28, 1994	E	038	A61K037/00
EP 666752 A4	September 11, 1996		000	A61K037/00
EP 666752 A1	August 16, 1995	E	000	A61K037/00
JP 08502492 W	March 19, 1996		043	A61K009/107

INT-CL (IPC): A61K 9/107; A61K 37/00; A61K 38/00; A61K 38/04; A61K 38/23; A61K 38/28; A61K 47/14

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: WO 9408603 A1, EP 671929 A4, EP 671929 A1, JP 08502490 W

L7: Entry 3 of 3

File: DWPI

Apr 28, 1994

DERWENT-ACC-NO: 1994-150933

DERWENT-WEEK: 199707

COPYRIGHT 2007 DERWENT INFORMATION LTD

TITLE: Water in oil microemulsion useful as oral or topical drug delivery vehicle  
 partic. for peptide(s) - comprises lipophilic phase contg inter-esterified  
 tri:glyceride and low HLB surfactant, high HLB surfactant, aq hydrophilic phase etc

INVENTOR: CONSTANTINIDES, P; CONSTANTINIDES, P P

PRIORITY-DATA: 1992US-0962956 (October 16, 1992)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 9408603 A1</u>	April 28, 1994	E	034	A61K037/00
<u>EP 671929 A4</u>	September 25, 1996		000	A61K037/00
<u>EP 671929 A1</u>	September 20, 1995	E	000	A61K037/00
<u>JP 08502490 W</u>	March 19, 1996		039	A61K047/06

INT-CL (IPC): A61K 37/00; A61K 37/02; A61K 37/26; A61K 38/00; A61K 38/04;  
 A61K 38/11; A61K 38/23; A61K 38/28; A61K 47/06

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	PubD	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Term	Documents
\$RENIN	0
RENIN	9812
ARENIN	7
CARENIN	3
ALPHA-CARENIN	2
BETA-CARENIN	1
SCIHARENIN	1
I5FIARENIN	1
KARENIN	7
CIS-KARENIN	2
(L6 AND \$RENIN) . PGPB, USPT, USOC, EPAB, JPAB, DWPI, TDBD.	3

There are more results than shown above. [Click here to view the entire set.](#)

Display Format:

1. Document ID: IN 200602180 P4, WO 2005058291 A1, AU 2004298758 A1, EP 1729748 A1, MX 2006006926 A1, BR 200417535 A, US 20070082016 A1, JP 2007514697 W, CN 1893932 A, KR 2006130072 A

L8: Entry 1 of 1

File: DWPI

Jun 8, 2007

DERWENT-ACC-NO: 2005-479200

DERWENT-WEEK: 200748

COPYRIGHT 2007 DERWENT INFORMATION LTD

TITLE: Oral composition useful to treat conditions associated with renin activity (e.g. hypertension), comprising delta-amino-gamma-hydroxy-omega-aryl-alka- noic acid amide renin inhibitor in absorption enhancing medium

INVENTOR: OTTINGER, I

PRIORITY-DATA: 2004US-547676P (February 25, 2004), 2003US-531562P (December 19, 2003), 2006US-0580258 (May 24, 2006)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>IN 200602180 P4</u>	June 8, 2007	E	000	A61K031/00
<u>WO 2005058291 A1</u>	June 30, 2005	E	027	A61K031/00
<u>AU 2004298758 A1</u>	June 30, 2005		000	A61K009/107
<u>EP 1729748 A1</u>	December 13, 2006	E	000	A61K031/00
<u>MX 2006006926 A1</u>	September 1, 2006		000	A61K031/00
<u>BR 200417535 A</u>	March 27, 2007		000	A61K031/00
<u>US 20070082016 A1</u>	April 12, 2007		000	A61K031/165
<u>JP 2007514697 W</u>	June 7, 2007		022	A61K009/107
<u>CN 1893932 A</u>	January 10, 2007		000	A61K031/00
<u>KR 2006130072 A</u>	December 18, 2006		000	A61K009/107

INT-CL (IPC): A61K 9/00; A61K 9/107; A61K 31/00; A61K 31/16; A61K 31/165; A61K 47/12; A61K 47/14; A61K 47/22; A61K 47/34; A61P 3/00; A61P 3/10; A61P 5/00; A61P 5/42; A61P 9/00; A61P 9/04; A61P 9/10; A61P 9/12; A61P 13/00; A61P 13/12; A61P 25/00; A61P 25/22; A61P 25/28; A61P 27/00; A61P 27/06; A61P 43/00

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EndC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Term	Documents
\$RENIN	0
RENIN	9812
ARENIN	7
CARENIN	3
ALPHA-CARENIN	2
BETA-CARENIN	1
SCIHARENIN	1

I5FIARENIN	1
KARENIN	7
CIS-KARENIN	2
(L4 AND \$RENIN NOT L7) .PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	1

There are more results than shown above. [Click here to view the entire set.](#)

---

**Display Format:**  **Change Format**